Stay updated on Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial page.

Latest updates to the Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe page's release notes show a new revision label (v3.6.5) replacing the previous v3.6.4, indicating a minor update to the page/system rather than substantive changes to the study details.SummaryDifference0.0%

- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedRevision: v3.6.4 has been added and Revision: v3.6.3 removed, indicating a minor version update to the page's release notes/metadata. This update updates the version label on the page to reflect a new release and may accompany small UI or data adjustments.SummaryDifference0.0%

- Check44 days agoChange DetectedA new publication related to the study has been added to Publications (Telisotuzumab Vedotin in c-Met+ NSCLC), and the page shows a new revision (v3.6.3) with the older version (v3.6.1) removed, indicating an updated study record.SummaryDifference0.0%

- Check51 days agoChange DetectedRevision updated from v3.6.0 to v3.6.1, representing a minor publication release of the page. No content changes are indicated by the change data.SummaryDifference0.0%

- Check65 days agoChange DetectedRecruitment is now shown as closed for this study, and new navigation links for How to Read a Study Record, Common Questions, and How to Join a Study have been added. There are also minor formatting tweaks to the Intervention/Treatment heading and to the revision notes.SummaryDifference0.1%

- Check73 days agoChange DetectedRevision version updated from v3.5.4 to v3.5.5, reflecting a minor update to the page's revision tracking.SummaryDifference0.0%

Stay in the know with updates to Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Telisotuzumab Vedotin in c-Met+ NSCLC Clinical Trial page.